[A study of influence of zafirlukast to anoxic pulmonary hypertension in rats].
OBJECTIVE
To investigate possible mechanism of the influence of zafirlukast to anoxic pulmonary hypertension in rats.


METHODS
Forty wistar rats were divided into four groups in random: (1) control group; (2) anoxic pulmonary hypertension group; (3) zafirlukast preventive group; (4) zafirlukast therapeutic group. Pulmonary arterial pressure was measured, naemo kinitic indexes were recorded.


RESULTS
In the anoxic group and control group, the difference of mPAP was remarkable, P < 0.01. When zafirlukast preventive group and the therapeutic group compared with the control group, there was no statistical difference, P > 0.05. When the preventive group and the therapeutic group compared with the hypoxia group, P < 0.01. In the hypoxia group, the content of NO in the plasma, broncho-alveolar lavage solution, and the lung tissue showed remarkable significance compared with that of control group, P < 0.01. The content of NO2-./NO3-. in the preventive group showed remarkable significance compared with hypoxia group, P < 0.05, P < 0.01. The content of NO2-./NO3-. in the therapeutic group showed remarkable significance compared with hypoxia group, P < 0.01. The content of collagen in hypoxia group was remarkable highened compared with that of control group, P < 0.01. The content of collagen in preventive group and therapeutic group showed remarkable significance compared with hypoxia group, P < 0.01, P < 0.05.


CONCLUSIONS
The results indicate that zafirlukast can lower anoxic pulmonary hypertension, one of its mechanisms may be related with its depressing the sediment of collagen on lung tissue, adjusting NO level in rats and anti-damaging effect of free radicals.
Pang
B
B
Beijing Institute of Respiratory Medicine, Beijing Red Cross Chaoyang Hospital of Capital University of Medical Sciences, Beijing 100020, China.
Wang
C
C
Zhou
J
J
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003094:Collagen / Q000032:analysis; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D000860:Hypoxia / Q000188:drug therapy*; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D048448:Phenylcarbamates; D011651:Pulmonary Artery / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides; D013482:Superoxide Dismutase / Q000378:metabolism; D014105:Tosyl Compounds / Q000627:therapeutic use*
D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D003094:Collagen; D013482:Superoxide Dismutase; C062735:zafirlukast